Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2026-01-23 pm EST			5-day change	1st Jan Change
108.18 ^USD	-0.92%		-0.60%	+2.77%

Jan. 22	SK Bioscience, MSD, and Hilleman Laboratories Advance Zaire Ebolavirus Vaccine Development with CEPI Funding	CI
Jan. 22	JPMorgan Adjusts Price Target on Merck & Co. to $125 From $120, Maintains Overweight Rating	MT

Health Rounds: Shingles vaccine reduces risk of death from dementia, study finds

Published on 12/05/2025 at 07:02 am EST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Merck & Co., Inc.

Jan. 22	SK Bioscience, MSD, and Hilleman Laboratories Advance Zaire Ebolavirus Vaccine Development with CEPI Funding	CI
Jan. 22	JPMorgan Adjusts Price Target on Merck & Co. to $125 From $120, Maintains Overweight Rating	MT
Jan. 21	US Equity Markets Rise After Trump Rules Out Using Force in Greenland Bid	MT
Jan. 21	Sector Update: Health Care Stocks Higher Late Afternoon	MT
Jan. 21	Sector Update: Health Care Stocks Rise in Afternoon Trading	MT
Jan. 21	Merck, CEPI Collaborate on More Affordable Ebola Vaccine	MT
Jan. 21	Merck unit partners with global health coalition to develop affordable Ebola vaccine	RE
Jan. 20	Global drugmakers rush to boost US presence as tariff threat looms	RE
Jan. 20	TD Cowen Adjusts Price Target on Merck to $120 From $100, Maintains Hold Rating	MT
Jan. 20	Leerink Partners Adjusts Price Target on Merck to $124 From $114, Maintains Outperform Rating	MT
Jan. 20	Moderna, Merck's Skin Cancer Therapy Shows 49% Lower Risk of Cancer in Mid-Stage Study	MT
Jan. 20	Correction to Moderna, Merck Cancer-Vaccine Story	DJ
Jan. 20	Moderna, Merck's skin cancer vaccine shows sustained benefit in five-year follow-up	RE
Jan. 20	Moderna, Merck Report Positive Results From Cancer-Vaccine Study	DJ
Jan. 20	Moderna, Merck's skin cancer vaccine shows sustained benefit after five years	RE
Jan. 20	Moderna says Keytruda combo shows sustained 5-yr improvement in main goal for cancer vaccine	RE
Jan. 20	Merck and Chemlex Sign Memorandum of Understanding to Advance Automated Chemistry and Technological Innovation	CI
Jan. 19	Guardant Health announces multi-year strategic collaboration agreement with Merck	RE
Jan. 19	Guardant Health, Inc. Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform	CI
Jan. 16	Where the Money's Moving
Jan. 16	Some drugmakers quietly concerned about legal risk with speedy FDA review program	RE
Jan. 15	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
Jan. 15	US FDA delays two drug reviews in new voucher program after safety, efficacy concerns	RE
Jan. 13	Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company	CI
Jan. 13	Illumina introduces Billion Cell Atlas, genome-wide genetic perturbation dataset	RE

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.4%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (20%); - sale of animal health products (9.2%); - other (1.4%). Net sales are distributed geographically as follows: the United States (50.3%), Europe/Middle East/Africa (21.8%), Latin America (5.4%), China (8.6%), Japan (5.1%), Asia/Pacific (4.8%) and other (4%).

Employees

74,000

Sector

Pharmaceuticals

Calendar

Feb. 03 - Q4 2025 Earnings Release

More about the company